

ASX Announcement

30 June 2021

Change of Company Secretary

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announces Sandra McIntosh has resigned as Company Secretary, effective 30 June 2021. Sandra has been with Regeneus since 2009 and the Board of Directors would like to thank Sandra for the tremendous contribution Sandra has made to Regeneus both as Company Secretary and Head of Corporate Operations.

The Company is pleased to announce that Hang Ling (Helen) Leung has been appointed Company Secretary of Regeneus, effective 1 July 2021. The Board welcomes Helen to the Company and looks forward to working with her.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com